Related Experiment Video
Updated: May 24, 2026
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression.
C A Derosa1, B Furusato, S Shaheduzzaman
1Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, MD 20852, USA.
Prostate Cancer and Prostatic Diseases
|February 21, 2012
Summary
Secreted protein acidic and rich in cysteine (SPARC) shows potential as a prognostic marker for aggressive prostate cancer (CaP). Higher SPARC protein levels in primary tumors correlate with metastasis development, aiding in predicting CaP progression.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Prostate cancer (CaP) is often detected early, but prognosis remains uncertain.
- Predictive markers for aggressive CaP progression are crucial for patient management.
- Identifying early prognostic markers is an active area of research.
Purpose of the Study:
- To identify early predictive markers for aggressive prostate cancer (CaP) progression.
- To analyze transcriptomes and identify key genes associated with tumor differentiation.
- To validate potential markers at both transcript and protein levels.
Main Methods:
- Comparative transcriptome analysis of well- and poorly differentiated (PD) prostate tumors (N=40).
- Validation using quantitative real-time RT-PCR (N=110) and immunohistochemistry (N=53) in an independent cohort.
- Analysis of gene expression networks and regulatory elements.
Main Results:
- A 12-gene network centered on SPARC was associated with the PD phenotype.
- SPARC mRNA expression correlated with poor differentiation and higher Gleason scores.
- Elevated SPARC protein levels predicted subsequent metastasis development (AUC=0.803).
Conclusions:
- SPARC evaluation in primary prostate tumors shows potential as a prognostic marker.
- SPARC may help predict metastatic progression in prostate cancer patients.
- This finding supports SPARC's role in understanding CaP aggressiveness.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...